Bacterial meningitis: an update of new treatment options

References

• van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004;351(18):1849-59
   PubMed Web of Science ®Google Scholar
• Miller LG, Choi C. Meningitiss in older patients: how to diagnose and treat a deadly infection. Geriatrics 1997;52(8):43-4.47-50.55
   PubMed Web of Science ®Google Scholar
• Schwerk C, Tenenbaum T, Kim KS, Schroten H. The choroid plexus-a multi-role player during infectious diseases of the CNS. Frontiers in Cellular Neuroscience 2015;9:80
   PubMed Web of Science ®Google Scholar
• Gerber J, Nau R. Mechanisms of injury in bacterial meningitis. Curr Opin Neurol 2013;23(3):312-18
   Web of Science ®Google Scholar
• van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet 2012;380(9854):1693-702
   Google Scholar
• Nau R, Bruck W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci 2002;25(1):38-45
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Coisne C. Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 2011;8(1):4
   PubMedGoogle Scholar
• Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature 2010;468(7321):253-62
   PubMed Web of Science ®Google Scholar
• Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev 2011;24(3):557-91
   PubMed Web of Science ®Google Scholar
• Barichello T, Generoso JS, Simoes LR, et al. Role of oxidative stress in the pathophysiology of pneumococcal meningitis. Oxidative Medicine and Cellular Longevity 2013;2013:371465
   PubMed Web of Science ®Google Scholar
• Barichello T, Collodel A, Generoso JS, et al. Targets for adjunctive therapy in pneumococcal meningitis. J Neuroimmunol 2015;278:262-70
   PubMed Web of Science ®Google Scholar
• Scheld WM, Dacey RG, Winn HR, et al. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis. Alterations with penicillin and methylprednisolone. J Clin Invest 1980;66(2):243-53
   PubMed Web of Science ®Google Scholar
• Kasanmoentalib ES, Brouwer MC, van der Ende A, van de Beek D. Hydrocephalus in adults with community-acquired bacterial meningitis. Neurology 2010;75(10):918-23
   PubMed Web of Science ®Google Scholar
• Bodilsen J, Schonheyder HC, Nielsen HI. Hydrocephalus is a rare outcome in community-acquired bacterial meningitis in adults: a retrospective analysis. BMC Infect Dis 2013;13(1):321
   PubMed Web of Science ®Google Scholar
• van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet 2012;380(9854):1693-702
   PubMed Web of Science ®Google Scholar
• Tsilidis KK, Panagiotou OA, Sena ES, et al. Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol 2013;11(7):e1001609
   PubMed Web of Science ®Google Scholar
• Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. Crit Care Med 2006;34(11):2758-65
   PubMed Web of Science ®Google Scholar
• Koster-Rasmussen R, Korshin A, Meyer CN. Antibiotic treatment delay and outcome in acute bacterial meningitis. J Infect 2008;57(6):449-54
   PubMed Web of Science ®Google Scholar
• Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med 2001;345(24):1727-33
   PubMed Web of Science ®Google Scholar
• Available from: www.dgn.org/images/stories/dgn/leitlinien/LL_2012/pdf/ll_34_ambulant_erworbene_bakterielle_eitrige_meningoenzephalitis.pdf
   Google Scholar
• Glimaker M, Johansson B, Grindborg O, et al. Adult bacterial meningitis: earlier treatment and improved outcome following guideline revision promoting prompt lumbar puncture. Clin Infect Dis 2015;60(8):1162-9
   PubMed Web of Science ®Google Scholar
• Tureen JH, Tauber MG, Sande MA. Effect of hydration status on cerebral blood flow and cerebrospinal fluid lactic acidosis in rabbits with experimental meningitis. J Clin Invest 1992;89(3):947-53
   PubMed Web of Science ®Google Scholar
• Maconochie IK, Bhaumik S. Fluid therapy for acute bacterial meningitis. Cochrane Database Syst Rev. Cochrane Database Syst Rev 2014;5:CD004786
   Google Scholar
• Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39(2):165-228
   PubMed Web of Science ®Google Scholar
• Available from: www.dgn.org/images/stories/dgn/leitlinien/LL_2012/pdf/ll_34_ambulant_erworbene_bakterielle_eitrige_meningoenzephalitis.pdf
   Google Scholar
• Glimaker M, Johansson B, Halldorsdottir H, et al. Neuro-intensive treatment targeting intracranial hypertension improves outcome in severe bacterial meningitis: an intervention-control study. PLoS One 2014;9(3):e91976
   PubMed Web of Science ®Google Scholar
• Baussart B, Cheisson G, Compain M, et al. Multimodal cerebral monitoring and decompressive surgery for the treatment of severe bacterial meningitis with increased intracranial pressure. Acta Anaesthesiol Scand 2006;50(6):762-5
   PubMed Web of Science ®Google Scholar
• Perin A, Nascimben E, Longatti P. Decompressive craniectomy in a case of intractable intracranial hypertension due to pneumococcal meningitis. Acta Neurochir (Wien) 2008;150(8):837-42
   PubMed Web of Science ®Google Scholar
• Bordes J, Boret H, Lacroix G, et al. Decompressive craniectomy guided by cerebral microdialysis and brain tissue oxygenation in a patient with meningitis. Acta Anaesthesiol Scand 2011;55(1):130-3
   PubMed Web of Science ®Google Scholar
• Imohl M, Reinert RR, Tulkens PM, van der Linden M. Penicillin susceptibility breakpoints for Streptococcus pneumoniae and their effect on susceptibility categorisation in Germany (1997-2013). Eur J Clin Microbiol 2014;33(11):2035-40
   Google Scholar
• Imohl M, Reinert RR, van der Linden M. Adult invasive pneumococcal disease between 2003 and 2006 in North-Rhine Westphalia, Germany: serotype distribution before recommendation for general pneumococcal conjugate vaccination for children <2 years of age. Clin Microbiol Infect 2009;15(11):1008-12
   PubMed Web of Science ®Google Scholar
• Erdem H, Elaldi N, Oztoprak N, et al. Mortality indicators in pneumococcal meningitis: therapeutic implications. Int J Infect Dis 2014;19:13-19
   PubMed Web of Science ®Google Scholar
• Gouveia EL, Reis JN, Flannery B, et al. Clinical outcome of pneumococcal meningitis during the emergence of pencillin-resistant Streptococcus pneumoniae: an observational study. BMC Infect Dis 2011;11:323
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Enriquez R, Abad R, et al. Antibiotic resistant meningococci in Europe: any need to act? FEMS Microbiol Rev 2007;31(1):64-70
   PubMed Web of Science ®Google Scholar
• Available from: www.dgn.org/images/stories/dgn/leitlinien/LL_2012/pdf/ll_34_ambulant_erworbene_bakterielle_eitrige_meningoenzephalitis.pdf
   Google Scholar
• Alvares JR, Mantese OC, Paula A, et al. Prevalence of pneumococcal serotypes and resistance to antimicrobial agents in patients with meningitis: ten-year analysis. Braz J Infect Dis 2011;15(1):22-7
   PubMed Web of Science ®Google Scholar
• Oftadeh S, Gidding HF, Gilbert GL. Laboratory surveillance of invasive pneumococcal disease in New South Wales, Australia, before and after introduction of 7-valent conjugate vaccine: reduced disease, but not antibiotic resistance rates. Epidemiol Infect 2013;141(9):1797-806
   PubMed Web of Science ®Google Scholar
• Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010;16(5):402-10
   Google Scholar
• Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009;360(3):244-56
   PubMed Web of Science ®Google Scholar
• Kumari VH, Babu AR, Srinivas D, et al. Methicillin-Resistant Staphylococcus aureus central nervous system infections - Analysis and outcome. British Journal of Neurosurgery 2015;29:413-8
   Google Scholar
• Konstantelias AA, Vardakas KZ, Polyzos KA, et al. Antimicrobial-impregnated and -coated shunt catheters for prevention of infections in patients with hydrocephalus: a systematic review and meta-analysis. J Neurosurg 2015;122(5):1096-112
   PubMed Web of Science ®Google Scholar
• Wang JS, Muzevich K, Edmond MB, et al. Central nervous system infections due to vancomycin-resistant enterococci: case series and review of the literature. Int J Infect Dis 2014;25:26-31
   PubMed Web of Science ®Google Scholar
• Kourbeti IS, Vakis AF, Ziakas P, et al. Infections in patients undergoing craniotomy: risk factors associated with post-craniotomy meningitis. J Neurosurg 2015;122(5):1113-19
   PubMed Web of Science ®Google Scholar
• Huang CR, Lu CH, Chang WN. Adult Enterobacter meningitis: a high incidence of coinfection with other pathogens and frequent association with neurosurgical procedures. Infection 2001;29(2):75-9
   PubMed Web of Science ®Google Scholar
• Pintado V, Pazos R, Jimenez-Mejias ME, et al. Methicillin-resistant Staphylococcus aureus meningitis in adults: a multicenter study of 86 cases. Medicine 2012;91(1):10-17
   PubMed Web of Science ®Google Scholar
• Conde-Pereira C, Rodas-Rodriguez L, Diaz-Paz M, et al. Fatal case of polymicrobial meningitis caused by Cryptococcus liquefaciens and Mycobacterium tuberculosis complex in a human immunodeficiency virus-infected patient. J Clin Microbiol 2015;53(8):2753-5
   Google Scholar
• Wang KW, Chang WN, Huang CR, et al. Post-neurosurgical nosocomial bacterial meningitis in adults: microbiology, clinical features, and outcomes. J Clin Neurosci 2005;12(6):647-50
   PubMed Web of Science ®Google Scholar
• Klugman KP, Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem meningitis study group. Antimicrob Agents Chemother 1995;39(5):1140-6
   PubMed Web of Science ®Google Scholar
• Schmutzhard E, Williams KJ, Vukmirovits G, et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. J Antimicrob Chemother 1995;36(Suppl A):85-97
   Google Scholar
• De Sarro A, Ammendola D, Zappala M, et al. Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother 1995;39(1):232-7
   PubMed Web of Science ®Google Scholar
• Kullar R, Chin JN, Edwards DJ, et al. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother 2011;55(7):3505-9
   PubMed Web of Science ®Google Scholar
• Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004;48(10):3928-33
   PubMed Web of Science ®Google Scholar
• Gerber P, Stucki A, Acosta F, et al. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 2006;57(4):720-3
   PubMed Web of Science ®Google Scholar
• Mook-Kanamori BB, Rouse MS, Kang CI, et al. Daptomycin in experimental murine pneumococcal meningitis. BMC Infect Dis 2009;9:50
   PubMed Web of Science ®Google Scholar
• Bardak-Ozcem S, Turhan T, Sipahi OR, et al. Daptomycin versus vancomycin in treatment of methicillin-resistant Staphylococcus aureus meningitis in an experimental rabbit model. Antimicrob Agents Chemother 2013;57(3):1556-8
   PubMed Web of Science ®Google Scholar
• Egermann U, Stanga Z, Ramin A, et al. Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone. Antimicrob Agents Chemother 2009;53(7):3030-3
   PubMed Web of Science ®Google Scholar
• Spanjaard L, Vandenbroucke-Grauls CM. Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid. Antimicrob Agents Chemother 2008;52(5):1850-1
   PubMed Web of Science ®Google Scholar
• Knoll BM, Hellmann M, Kotton CN. Vancomycin-resistant enterococcus faecium meningitis in adults: case series and review of the literature. Scand J Infect Dis 2013;45(2):131-9
   PubMed Web of Science ®Google Scholar
• Vena A, Falcone M, Comandini E, et al. Daptomycin plus trimethoprim/sulfamethoxazole combination therapy in post-neurosurgical meningitis caused by linezolid-resistant Staphylococcus epidermidis. Diagn Microbiol Infect Dis 2013;76(1):99-102
   PubMed Web of Science ®Google Scholar
• Jaspan HB, Brothers AW, Campbell AJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 2010;29(4):379-81
   PubMed Web of Science ®Google Scholar
• Erritouni M, Ktaich N, Rahal JJ, et al. Use of daptomycin for the treatment of methicillin-resistant coagulase-negative staphylococcal ventriculitis. Case Rep Med 2012;2012:593578
   PubMedGoogle Scholar
• Mueller SW, Kiser TH, Anderson TA, Neumann RT. Intraventricular daptomycin and intravenous linezolid for the treatment of external ventricular-drain-associated ventriculitis due to vancomycin-resistant Enterococcus faecium. Ann Pharmacother 2012;46(12):e35
   PubMedGoogle Scholar
• Alffenaar JW, van Altena R, Bokkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 2009;49(7):1080-2
   PubMed Web of Science ®Google Scholar
• Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010;23(4):858-83
   PubMed Web of Science ®Google Scholar
• Nau R, Schmidt T, Kaye K, et al. Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 1995;39(3):593-7
   PubMed Web of Science ®Google Scholar
• Nau R, Zysk G, Schmidt H, et al. Trovafloxacin delays the antibiotic-induced inflammatory response in experimental pneumococcal meningitis. J Antimicrob Chemother 1997;39(6):781-8
   PubMed Web of Science ®Google Scholar
• Cottagnoud P, Acosta F, Cottagnoud M, et al. Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. Antimicrob Agents Chemother 2000;44(8):2179-81
   PubMed Web of Science ®Google Scholar
• Djukic M, Bottcher T, Wellmer A, et al. Moxifloxacin in experimental Streptococcus pneumoniae cerebritis and meningitis. Neurocrit Care 2005;2(3):325-9
   PubMed Web of Science ®Google Scholar
• Schmidt H, Dalhoff A, Stuertz K, et al. Moxifloxacin in the therapy of experimental pneumococcal meningitis. Antimicrob Agents Chemother 1998;42(6):1397-407
   PubMed Web of Science ®Google Scholar
• Rodriguez-Cerrato V, McCoig CC, Michelow IC, et al. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother 2001;45(11):3092-7
   PubMed Web of Science ®Google Scholar
• Sipahi OR, Turhan T, Pullukcu H, et al. Moxifloxacin versus ampicillin + gentamicin in the therapy of experimental Listeria monocytogenes meningitis. J Antimicrob Chemother 2008;61(3):670-3
   PubMed Web of Science ®Google Scholar
• Ostergaard C, Sorensen TK, Knudsen JD, Frimodt-Moller N. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob Agents Chemother 1998;42(7):1706-12
   PubMed Web of Science ®Google Scholar
• Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;13(1):27-35
   PubMed Web of Science ®Google Scholar
• European medicines agency. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Moxifloxacin/human_referral_000114.jsp&mid=WC0b01ac0580024e9a
   Google Scholar
• Beer R, Engelhardt KW, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007;51(1):379-82
   PubMed Web of Science ®Google Scholar
• Villani P, Regazzi MB, Marubbi F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002;46(3):936-7
   PubMed Web of Science ®Google Scholar
• Peltola H, Anttila M, Renkonen OV. Randomised comparison of chloramphenicol, ampicillin, cefotaxime, and ceftriaxone for childhood bacterial meningitis. Finnish Study Group. Lancet 1989;1(8650):1281-7
   PubMed Web of Science ®Google Scholar
• Rupprecht TA, Pfister HW. Clinical experience with linezolid for the treatment of central nervous system infections. Eur J Neurol 2005;12(7):536-42
   PubMed Web of Science ®Google Scholar
• Sipahi OR, Bardak S, Turhan T, et al. Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: a series of 17 cases. Scand J Infect Dis 2011;43(10):757-64
   PubMed Web of Science ®Google Scholar
• Frasca KL, Schuster MG. Vancomycin-resistant enterococcal meningitis in an autologous stem cell transplant recipient cured with linezolid. Transpl Infect Dis 2013;15(1):E1-4
   PubMed Web of Science ®Google Scholar
• Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010;50(6):821-5
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006;58(6):1221-9
   PubMed Web of Science ®Google Scholar
• Ray L, Levasseur K, Nicolau DP, Scheetz MH. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Ann Pharmacother 2010;44(3):582-6
   PubMed Web of Science ®Google Scholar
• Lengerke C, Haap M, Mayer F, et al. Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges. Antimicrob Agents Chemother 2011;55(1):449-50
   PubMed Web of Science ®Google Scholar
• Tutuncu EE, Kuscu F, Gurbuz Y, et al. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis 2010;14 Suppl 3:e224-6
   PubMed Web of Science ®Google Scholar
• Garrison MW, Kawamura NM, Wen MM. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. Expert Rev Anti Infect Ther 2012;10(10):1087-103
   PubMed Web of Science ®Google Scholar
• Patel SN, Pillai DR, Pong-Porter S, et al. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother 2009;64(3):659-60
   PubMed Web of Science ®Google Scholar
• Stucki A, Cottagnoud M, Acosta F, et al. Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (beta-lactamase positive and beta-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model. Antimicrob Agents Chemother 2012;56(2):921-5
   PubMed Web of Science ®Google Scholar
• Balouch MA, Bajwa RJ, Hassoun A. Successful use of ceftaroline for the treatment of MRSA meningitis secondary to an infectious complication of lumbar spine surgery. J Antimicrob Chemother 2015;70(2):624-5
   PubMed Web of Science ®Google Scholar
• Kuriakose SS, Rabbat M, Gallagher JC. Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis. J Antimicrob Chemother 2015;70(3):953-4
   PubMed Web of Science ®Google Scholar
• Stucki A, Gerber P, Acosta F, et al. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 2006;50(2):770-3
   PubMed Web of Science ®Google Scholar
• Nnedu ON, Pankey GA. Update on the emerging role of telavancin in hospital-acquired infections. Therapeutics and Clinical Risk Management 2015;11:605-10
   PubMed Web of Science ®Google Scholar
• Pelkonen T, Roine I, Cruzeiro ML, et al. Slow initial beta-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: a randomised, controlled trial. Lancet Infect Dis 2011;11(8):613-21
   PubMed Web of Science ®Google Scholar
• Roberts JA, Boots R, Rickard CM, et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007;59(2):285-91
   PubMed Web of Science ®Google Scholar
• Nau R, Prange HW, Muth P, et al. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother 1993;37(7):1518-24
   PubMed Web of Science ®Google Scholar
• Stuertz K, Schmidt H, Eiffert H, et al. Differential release of lipoteichoic and teichoic acids from Streptococcus pneumoniae as a result of exposure to beta-lactam antibiotics, rifamycins, trovafloxacin, and quinupristin-dalfopristin. Antimicrob Agents Chemother 1998;42(2):277-81
   PubMed Web of Science ®Google Scholar
• Shiu J, Wang E, Tejani AM, Wasdell M. Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev 2013;3:CD008481
   Google Scholar
• Webster DP, Griffiths S, Bowler IC. Failure of linezolid therapy for post-neurosurgical meningitis due to Enterococcus faecium. J Antimicrob Chemother 2009;63(3):622-3
   PubMed Web of Science ®Google Scholar
• Vivas M, Force E, Garrigos C, et al. Experimental study of the efficacy of daptomycin for the treatment of cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother 2014;69(11):3020-6
   PubMed Web of Science ®Google Scholar
• Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant acinetobacter species. Lancet Infect Dis 2009;9(4):245-55
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Karvanen M, Iosifidis E, et al. Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob Agents Chemother 2010;54(9):3985-7
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Amaya-Villar R. Multiresistant acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010;23(4):332-9
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Galani L, Baziaka F, Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents 2013;41(6):499-508
   PubMed Web of Science ®Google Scholar
• Hanninen P, Rossi T. Penetration of sulbactam into cerebrospinal fluid of patients with viral meningitis or without meningitis. Rev Infect Dis 1986;8 Suppl 5:S609-11
   PubMedGoogle Scholar
• Stahl JP, Bru JP, Fredj G, et al. Penetration of sulbactam into the cerebrospinal fluid of patients with bacterial meningitis receiving ampicillin therapy. Rev Infect Dis 1986;8 Suppl 5:S612-16
   PubMedGoogle Scholar
• Foulds G, McBride TJ, Knirsch AK, et al. Penetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitis. Antimicrob Agents Chemother 1987;31(11):1703-5
   PubMed Web of Science ®Google Scholar
• Jimenez-Mejias ME, Pachon J, Becerril B, et al. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997;24(5):932-5
   PubMed Web of Science ®Google Scholar
• Cawley MJ, Suh C, Lee S, Ackerman BH. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant acinetobacter baumannii meningitis. Pharmacotherapy 2002;22(4):527-32
   PubMed Web of Science ®Google Scholar
• McCracken GHJr, Mize SG, Threlkeld N. Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. Lancet 1980;1(8172):787-91
   PubMed Web of Science ®Google Scholar
• Odio CM, Faingezicht I, Paris M, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991;324(22):1525-31
   PubMed Web of Science ®Google Scholar
• Scheld WM, Brodeur JP. Effect of methylprednisolone on entry of ampicillin and gentamicin into cerebrospinal fluid in experimental pneumococcal and Escherichia coli meningitis. Antimicrob Agents Chemother 1983;23(1):108-12
   PubMed Web of Science ®Google Scholar
• Paris MM, Hickey SM, Trujillo M, et al. Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1995;39(6):1243-6
   PubMed Web of Science ®Google Scholar
• Paris MM, Hickey SM, Uscher MI, et al. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1994;38(6):1320-4
   PubMed Web of Science ®Google Scholar
• Ricard JD, Wolff M, Lacherade JC, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis 2007;44(2):250-5
   PubMed Web of Science ®Google Scholar
• Nau R, Wellmer A, Soto A, et al. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J Infect Dis 1999;179(6):1557-60
   PubMed Web of Science ®Google Scholar
• Focke NK, Kallenberg K, Mohr A, et al. Distributed, Limbic Gray Matter Atrophy in Patients after Bacterial Meningitis. AJNR Am J Neuroradiol 2012;34(6):1164-7
   Google Scholar
• Schmidt H, Heimann B, Djukic M, et al. Neuropsychological sequelae of bacterial and viral meningitis. Brain 2006;129(Pt 2):333-45
   PubMed Web of Science ®Google Scholar
• Nau R, Schmidt H. Long-term neuropsychological deficits after central nervous system infections despite adequate therapy. J Neurol 2007;254(Suppl 2):II80-3
   PubMedGoogle Scholar
• Zysk G, Bruck W, Gerber J, et al. Anti-inflammatory treatment influences neuronal apoptotic cell death in the dentate gyrus in experimental pneumococcal meningitis. J Neuropathol Exp Neurol 1996;55(6):722-8
   PubMed Web of Science ®Google Scholar
• Leib SL, Kim YS, Chow LL, et al. Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B streptococci. J Clin Invest 1996;98(11):2632-9
   PubMed Web of Science ®Google Scholar
• Leib SL, Heimgartner C, Bifrare YD, et al. Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats. Pediatr Res 2003;54(3):353-7
   PubMed Web of Science ®Google Scholar
• Weisfelt M, Hoogman M, van de Beek D, et al. Dexamethasone and long-term outcome in adults with bacterial meningitis. Ann Neurol 2006;60(4):456-68
   PubMed Web of Science ®Google Scholar
• de Gans J, van de Beek D. European Dexamethasone in Adulthood Bacterial Meningitis Study I. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347(20):1549-56
   PubMed Web of Science ®Google Scholar
• van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 2010;9(3):254-63
   PubMed Web of Science ®Google Scholar
• Esposito S, Semino M, Picciolli I, Principi N. Should corticosteroids be used in bacterial meningitis in children? Eur J Paediatr Neurol 2013;17(1):24-8
   PubMed Web of Science ®Google Scholar
• Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 2010;23(3):467-92
   PubMed Web of Science ®Google Scholar
• Heckenberg SG, Brouwer MC, van der Ende A, van de Beek D. Adjunctive dexamethasone in adults with meningococcal meningitis. Neurology 2012;79(15):1563-9
   PubMed Web of Science ®Google Scholar
• Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2013;6:CD004405
   Google Scholar
• Ambulant erworbene bakterielle (eitrige) Meningoenzephalitis. Available from: www.dgn.org/component/content/article/45-leitlinien-der-dgn-2012/2398-ll-34-ambulant-erworbene-bakterielle-eitrige-meningoenzephalitis.html?q=meningoenzephalitis
   Google Scholar
• Nau R. Osmotherapy for elevated intracranial pressure: a critical reappraisal. Clin Pharmacokinet 2000;38(1):23-40
   PubMed Web of Science ®Google Scholar
• Singhi S, Jarvinen A, Peltola H. Increase in serum osmolality is possible mechanism for the beneficial effects of glycerol in childhood bacterial meningitis. Pediatr Infect Dis J 2008;27(10):892-6
   PubMed Web of Science ®Google Scholar
• Schmidt H, Stuertz K, Chen V, et al. Glycerol does not reduce neuronal damage in experimental Streptococcus pneumoniae meningitis in rabbits. Inflammopharmacology 1998;6(1):19-26
   PubMedGoogle Scholar
• Blaser C, Klein M, Grandgirard D, et al. Adjuvant glycerol is not beneficial in experimental pneumococcal meningitis. BMC Infect Dis 2010;10:84
   PubMed Web of Science ®Google Scholar
• Peltola H, Roine I, Fernandez J, et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2007;45(10):1277-86
   PubMed Web of Science ®Google Scholar
• Ajdukiewicz KM, Cartwright KE, Scarborough M, et al. Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. Lancet Infect Dis 2011;11(4):293-300
   PubMed Web of Science ®Google Scholar
• Molyneux EM, Kawaza K, Phiri A, et al. Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children. Pediatr Infect Dis J 2014;33(2):214-16
   PubMed Web of Science ®Google Scholar
• Wall EC, Ajdukiewicz KM, Heyderman RS, Garner P. Osmotic therapies added to antibiotics for acute bacterial meningitis. Cochrane Database Syst Rev 2013;3:CD008806
   Google Scholar
• Nau R, Soto A, Bruck W. Apoptosis of neurons in the dentate gyrus in humans suffering from bacterial meningitis. J Neuropathol Exp Neurol 1999;58(3):265-74
   PubMed Web of Science ®Google Scholar
• Edwards GE. The use of hypothermia in a case of measles meningo-encephalitis. J Ir Med Assoc 1958;42(252):181-3
   PubMedGoogle Scholar
• Robinson A, Buckler JM. Emergency hypothermia in meningococcal meningitis. Lancet 1965;1(7376):81-3
   PubMed Web of Science ®Google Scholar
• Veghelyi PV. Emergency hypothermic in meningococcal meningitis. Lancet 1965;1(7387):710
   PubMed Web of Science ®Google Scholar
• Cuthbertson BH, Dickson R, Mackenzie A. Intracranial pressure measurement, induced hypothermia and barbiturate coma in meningitis associated with intractable raised intracranial pressure. Anaesthesia 2004;59(9):908-11
   PubMed Web of Science ®Google Scholar
• Lepur D, Kutlesa M, Barsic B. Induced hypothermia in adult community-acquired bacterial meningitis–more than just a possibility? J Infect 2011;62(2):172-7
   PubMed Web of Science ®Google Scholar
• Irazuzta JE, Pretzlaff RK, Zingarelli B, et al. Modulation of nuclear factor-kappaB activation and decreased markers of neurological injury associated with hypothermic therapy in experimental bacterial meningitis. Crit Care Med 2002;30(11):2553-9
   PubMed Web of Science ®Google Scholar
• Angstwurm K, Reuss S, Freyer D, et al. Induced hypothermia in experimental pneumococcal meningitis. J Cereb Blood Flow Metab 2000;20(5):834-8
   PubMed Web of Science ®Google Scholar
• Mourvillier B, Tubach F, van de Beek D, et al. Induced hypothermia in severe bacterial meningitis: a randomized clinical trial. JAMA 2013;310(20):2174-83
   PubMed Web of Science ®Google Scholar
• Kuikka A, Sivonen A, Emelianova A, Valtonen VV. Prognostic factors associated with improved outcome of Escherichia coli bacteremia in a Finnish university hospital. Eur J Clin Microbiol 1997;16(2):125-34
   Google Scholar
• Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol 1998;17(10):701-8
   Google Scholar
• Roine I, Peltola H, Fernandez J, et al. Influence of admission findings on death and neurological outcome from childhood bacterial meningitis. Clin Infect Dis 2008;46(8):1248-52
   PubMed Web of Science ®Google Scholar
• ARRIVE guidelines. Available from: www.nc3rs.org.uk/arrive-guidelines
   Google Scholar
• Tauber SC, Stadelmann C, Spreer A, et al. Increased expression of BDNF and proliferation of dentate granule cells after bacterial meningitis. J Neuropathol Exp Neurol 2005;64(9):806-15
   PubMed Web of Science ®Google Scholar
• Barichello T, Generoso JS, Simoes LR, et al. Vitamin B6 prevents cognitive impairment in experimental pneumococcal meningitis. Exp Biol Med 2014;239(10):1360-5
   PubMed Web of Science ®Google Scholar
• Zysset-Burri DC, Bellac CL, Leib SL, Wittwer M. Vitamin B6 reduces hippocampal apoptosis in experimental pneumococcal meningitis. BMC Infect Dis 2013;13:393
   PubMed Web of Science ®Google Scholar
• Barichello T, Generoso JS, Simoes LR, et al. Folic acid prevented cognitive impairment in experimental pneumococcal meningitis. J Neural Transm 2015;122(5):643-51
   PubMed Web of Science ®Google Scholar
• Djukic M, Onken ML, Schutze S, et al. Vitamin d deficiency reduces the immune response, phagocytosis rate, and intracellular killing rate of microglial cells. Infect Immun 2014;82(6):2585-94
   PubMed Web of Science ®Google Scholar
• Djukic M, Sostmann N, Bertsch T, et al. Vitamin D deficiency decreases survival of bacterial meningoencephalitis in mice. J Neuroinflammation 2015;12(1):208
   PubMed Web of Science ®Google Scholar
• Gerber J, Redlich S, Ribes S, et al. Intrathecal treatment with the anti-phosphorylcholine monoclonal antibody TEPC-15 decreases neuronal damage in experimental pneumococcal meningitis. Chemotherapy 2012;58(3):212-16
   PubMed Web of Science ®Google Scholar
• Nataf S, Stahel PF, Davoust N, Barnum SR. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci 1999;22(9):397-402
   PubMed Web of Science ®Google Scholar
• Mabbott NA, Bruce ME, Botto M, et al. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med 2001;7(4):485-7
   PubMed Web of Science ®Google Scholar
• Tuomanen E, Hengstler B, Zak O, Tomasz A. The role of complement in inflammation during experimental pneumococcal meningitis. Microb Pathog 1986;1(1):15-32
   PubMed Web of Science ®Google Scholar
• Woehrl B, Brouwer MC, Murr C, et al. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest 2011;121(10):3943-53
   PubMed Web of Science ®Google Scholar
• Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002;15(1):95-110
   PubMed Web of Science ®Google Scholar
• Ribes S, Adam N, Schutze S, et al. The nucleotide-binding oligomerization domain-containing-2 ligand muramyl dipeptide enhances phagocytosis and intracellular killing of Escherichia coli K1 by Toll-like receptor agonists in microglial cells. J Neuroimmunol 2012;252(1-2):16-23
   Google Scholar
• Jarisch A. Therapeutische Versuche bei Syphilis. Wien Med Wochenschr 1895;45:721-4
   Google Scholar
• Herxheimer K, Krause K. Über eine bei Syphilitischen vorkommende Quecksilberreaktion. Dtsch Med Wochenschr 1902;28:895-7
   Google Scholar
• Hopkin DA. Frapper fort ou frapper doucement: a gram-negative dilemma. Lancet 1978;2(8101):1193-4
   PubMed Web of Science ®Google Scholar
• Ahmed A, Jafri H, Lutsar I, et al. Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1999;43(4):876-81
   PubMed Web of Science ®Google Scholar
• Spreer A, Lugert R, Stoltefaut V, et al. Short-term rifampicin pretreatment reduces inflammation and neuronal cell death in a rabbit model of bacterial meningitis. Crit Care Med 2009;37(7):2253-8
   PubMed Web of Science ®Google Scholar
• Schneider O, Michel U, Zysk G, et al. Clinical outcome in pneumococcal meningitis correlates with CSF lipoteichoic acid concentrations. Neurology 1999;53(7):1584-7
   PubMed Web of Science ®Google Scholar
• Aubry-Damon H, Soussy CJ, Courvalin P. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1998;42(10):2590-4
   PubMed Web of Science ®Google Scholar
• Enright M, Zawadski P, Pickerill P, Dowson CG. Molecular evolution of rifampicin resistance in Streptococcus pneumoniae. Microb Drug Resist 1998;4(1):65-70
   PubMed Web of Science ®Google Scholar
• Gerber J, Pohl K, Sander V, et al. Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone. Antimicrob Agents Chemother 2003;47(4):1313-17
   PubMed Web of Science ®Google Scholar
• Spreer A, Kerstan H, Bottcher T, et al. Reduced release of pneumolysin by streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob Agents Chemother 2003;47(8):2649-54
   PubMed Web of Science ®Google Scholar
• Azeh I, Gerber J, Wellmer A, et al. Protein synthesis inhibiting clindamycin improves outcome in a mouse model of staphylococcus aureus sepsis compared with the cell wall active ceftriaxone. Crit Care Med 2002;30(7):1560-4
   PubMed Web of Science ®Google Scholar
• Bottcher T, Ren H, Goiny M, et al. Clindamycin is neuroprotective in experimental Streptococcus pneumoniae meningitis compared with ceftriaxone. J Neurochem 2004;91(6):1450-60
   PubMed Web of Science ®Google Scholar
• Grandgirard D, Burri M, Agyeman P, Leib SL. Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis. Antimicrob Agents Chemother 2012;56(8):4289-95
   PubMed Web of Science ®Google Scholar
• Grandgirard D, Schurch C, Cottagnoud P, Leib SL. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2007;51(6):2173-8
   PubMed Web of Science ®Google Scholar
• Barichello T, Goncalves JC, Generoso JS, et al. Attenuation of cognitive impairment by the nonbacteriolytic antibiotic daptomycin in Wistar rats submitted to pneumococcal meningitis. BMC Neurosci 2013;14:42
   PubMed Web of Science ®Google Scholar
• Vivas M, Force E, Tubau F, et al. Effect of dexamethasone on the efficacy of daptomycin in the therapy of experimental pneumococcal meningitis. Int J Antimicrob Agents 2015;46(1):28-32
   Google Scholar
• Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003;100(4):1966-71
   PubMed Web of Science ®Google Scholar
• Ebert S, Gerber J, Bader S, et al. Dose-dependent activation of microglial cells by Toll-like receptor agonists alone and in combination. J Neuroimmunol 2005;159(1-2):87-96
   PubMed Web of Science ®Google Scholar
• Hanke ML, Kielian T. Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci (Lond) 2011;121(9):367-87
   PubMed Web of Science ®Google Scholar
• Shirey KA, Lai W, Scott AJ, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 2013;497(7450):498-502
   PubMed Web of Science ®Google Scholar
• Goos M, Lange P, Hanisch UK, et al. Fibronectin is elevated in the cerebrospinal fluid of patients suffering from bacterial meningitis and enhances inflammation caused by bacterial products in primary mouse microglial cell cultures. J Neurochem 2007;102(6):2049-60
   PubMed Web of Science ®Google Scholar
• Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013;309(11):1154-62
   PubMed Web of Science ®Google Scholar
• Azeh I, Mader M, Smirnov A, et al. Experimental pneumococcal meningitis in rabbits: the increase of matrix metalloproteinase-9 in cerebrospinal fluid correlates with leucocyte invasion. Neurosci Lett 1998;256(3):127-30
   PubMed Web of Science ®Google Scholar
• Leppert D, Leib SL, Grygar C, et al. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin Infect Dis 2000;31(1):80-4
   PubMed Web of Science ®Google Scholar
• Ricci S, Grandgirard D, Wenzel M, et al. Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. BMC Infect Dis 2014;14(1):3853
   Web of Science ®Google Scholar
• Baranger K, Rivera S, Liechti FD, et al. Endogenous and synthetic MMP inhibitors in CNS physiopathology. Prog Brain Res 2014;214:313-51
   PubMed Web of Science ®Google Scholar
• Liechti FD, Bachtold F, Grandgirard D, et al. The matrix metalloproteinase inhibitor RS-130830 attenuates brain injury in experimental pneumococcal meningitis. J Neuroinflammation 2015;12(1):43
   PubMed Web of Science ®Google Scholar
• Liechti FD, Grandgirard D, Leppert D, Leib SL. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun 2014;82(4):1710-18
   PubMed Web of Science ®Google Scholar
• Barichello T, Generoso JS, Michelon CM, et al. Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats. Exp Biol Med 2014;239(2):225-31
   Web of Science ®Google Scholar
• Koedel U, Pfister HW. Protective effect of the antioxidant N-acetyl-L-cysteine in pneumococcal meningitis in the rat. Neurosci Lett 1997;225(1):33-6
   PubMed Web of Science ®Google Scholar
• Auer M, Pfister LA, Leppert D, et al. Effects of clinically used antioxidants in experimental pneumococcal meningitis. J Infect Dis 2000;182(1):347-50
   PubMed Web of Science ®Google Scholar
• Klein M, Koedel U, Pfister HW, Kastenbauer S. Meningitis-associated hearing loss: protection by adjunctive antioxidant therapy. Ann Neurol 2003;54(4):451-8
   PubMed Web of Science ®Google Scholar
• Hogen T, Demel C, Giese A, et al. Adjunctive N-acetyl-L-cysteine in murine pneumococcal meningitis. Antimicrob Agents Chemother 2013;57(10):4825-30
   Google Scholar
• Sheu JN, Liao WC, Wu UI, et al. Resveratrol suppresses calcium-mediated microglial activation and rescues hippocampal neurons of adult rats following acute bacterial meningitis. Comp Immunol Microbiol Infect Dis 2013;36(2):137-48
   PubMed Web of Science ®Google Scholar
• Gerber J, Lotz M, Ebert S, et al. Melatonin is neuroprotective in experimental Streptococcus pneumoniae meningitis. J Infect Dis 2005;191(5):783-90
   PubMed Web of Science ®Google Scholar
• Wu UI, Mai FD, Sheu JN, et al. Melatonin inhibits microglial activation, reduces pro-inflammatory cytokine levels, and rescues hippocampal neurons of adult rats with acute Klebsiella pneumoniae meningitis. J Pineal Res 2011;50(2):159-70
   PubMed Web of Science ®Google Scholar
• Spreer A, Gerber J, Baake D, et al. Antiinflammatory but no neuroprotective effects of melatonin under clinical treatment conditions in rabbit models of bacterial meningitis. J Neurosci Res 2006;84(7):1575-9
   PubMed Web of Science ®Google Scholar
• Barichello T, Ceretta RA, Generoso JS, et al. Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis. Eur J Pharmacol 2012;697(1-3):158-64
   PubMed Web of Science ®Google Scholar
• Nau R, Zettl U, Gerber J, et al. Granulocytes in the subarachnoid space of humans and rabbits with bacterial meningitis undergo apoptosis and are eliminated by macrophages. Acta Neuropathol 1998;96(5):472-80
   PubMed Web of Science ®Google Scholar
• Koedel U, Frankenberg T, Kirschnek S, et al. Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal meningitis. PLoS Pathog 2009;5(5):e1000461
   PubMed Web of Science ®Google Scholar
• Hoogendijk AJ, Roelofs JJ, Duitman J, et al. R-roscovitine reduces lung inflammation induced by lipoteichoic acid and Streptococcus pneumoniae. Mol Med 2012;18:1086-95
   PubMed Web of Science ®Google Scholar
• Krystof V, Uldrijan S. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 2010;11(3):291-302
   PubMed Web of Science ®Google Scholar
• Wache C, Klein M, Ostergaard C, et al. Myeloid-Related Protein 14 Promotes Inflammation and Injury in Meningitis. J Infect Dis 2015;212(2):247-57
   PubMed Web of Science ®Google Scholar
• Hohne C, Wenzel M, Angele B, et al. High mobility group box 1 prolongs inflammation and worsens disease in pneumococcal meningitis. Brain 2013;136(Pt 6):1746-59
   PubMed Web of Science ®Google Scholar
• Gerber J, Bottcher T, Bering J, et al. Increased neurogenesis after experimental Streptococcus pneumoniae meningitis. J Neurosci Res 2003;73(4):441-6
   PubMed Web of Science ®Google Scholar
• Gerber J, Tauber SC, Armbrecht I, et al. Increased neuronal proliferation in human bacterial meningitis. Neurology 2009;73(13):1026-32
   PubMed Web of Science ®Google Scholar
• Liebetanz D, Gerber J, Schiffner C, et al. Pre-infection physical exercise decreases mortality and stimulates neurogenesis in bacterial meningitis. J Neuroinflammation 2012;9:168
   PubMed Web of Science ®Google Scholar
• Barichello T, Fagundes GD, Generoso JS, et al. Environmental enrichment restores cognitive deficits induced by experimental childhood meningitis. Revista Brasileira de Psiquiatria 2014;36(4):322-9
   PubMed Web of Science ®Google Scholar
• Tauber SC, Harms K, Falkenburger B, et al. Modulation of hippocampal neuroplasticity by Fas/CD95 regulatory protein 2 (Faim2) in the course of bacterial meningitis. J Neuropathol Exp Neurol 2014;73(1):2-13
   PubMed Web of Science ®Google Scholar
• Schmidt AK, Reich A, Falkenburger B, et al. Adjuvant granulocyte colony-stimulating factor therapy results in improved spatial learning and stimulates hippocampal neurogenesis in a mouse model of pneumococcal meningitis. J Neuropathol Exp Neurol 2015;74(1):85-94
   PubMed Web of Science ®Google Scholar
• Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269(2):221-6
   PubMed Web of Science ®Google Scholar
• Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008;66(9):378-83
   PubMed Web of Science ®Google Scholar
• Davis S, Feikin D, Johnson HL. The effect of Haemophilus influenzae type B and pneumococcal conjugate vaccines on childhood meningitis mortality: a systematic review. BMC Public Health 2013;13 Suppl 3:S21
   PubMed Web of Science ®Google Scholar
• Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17(5):840-7
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Flood JS, Ramsay ME, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 2012;30(24):3710-16
   PubMed Web of Science ®Google Scholar
• Leca M, Bornet C, Montana M, et al. Meningococcal vaccines: Current state and future outlook. Pathol Biol (Paris) 2015;63(3):144-51
   Google Scholar
• Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012;307(6):573-82
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384(9960):2123-31
   PubMed Web of Science ®Google Scholar
• Block SL, Szenborn L, Daly W, et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Vaccine 2015;33(21):2500-10
   PubMed Web of Science ®Google Scholar
• Gamez G, Hammerschmidt S. Combat pneumococcal infections: adhesins as candidates for protein-based vaccine development. Curr Drug Targets 2012;13(3):323-37
   PubMed Web of Science ®Google Scholar
• Ribes S, Riegelmann J, Redlich S, et al. Multivalent choline dendrimers phagocytosis of Streptococcus pneumoniae R6 by microglial cells. Chemotherapy 2013;59(2):138-42
   Google Scholar
• Ratilal BO, Costa J, Pappamikail L, Sampaio C. Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. Cochrane Database Syst Rev 2015;4:CD004884
   Google Scholar
• Kim KS. Current concepts on the pathogenesis of Escherichia coli meningitis: implications for therapy and prevention. Curr Opin Infect Dis 2012;25(3):273-8
   PubMed Web of Science ®Google Scholar
• Tan YC, Gill AK, Kim KS. Treatment strategies for central nervous system infections: an update. Expert Opin Pharmacother 2015;16(2):187-203
   PubMed Web of Science ®Google Scholar
• Ribes S, Ebert S, Regen T, et al. Toll-like receptor stimulation enhances phagocytosis and intracellular killing of nonencapsulated and encapsulated Streptococcus pneumoniae by murine microglia. Infect Immun 2010;78(2):865-71
   PubMed Web of Science ®Google Scholar
• Ribes S, Adam N, Schutze S, et al. The nucleotide-binding oligomerization domain-containing-2 ligand muramyl dipeptide enhances phagocytosis and intracellular killing of Escherichia coli K1 by Toll-like receptor agonists in microglial cells. J Neuroimmunol 2012;252(1-2):16-23
   PubMed Web of Science ®Google Scholar
• Ribes S, Meister T, Ott M, et al. Intraperitoneal prophylaxis with CpG oligodeoxynucleotides protects neutropenic mice against intracerebral Escherichia coli K1 infection. J Neuroinflammation 2014;11:14
   PubMed Web of Science ®Google Scholar
• Muccioli GG, Stella N. Microglia produce and hydrolyze palmitoylethanolamide. Neuropharmacology 2008;54(1):16-22
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Davis JB, Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 2001;506(3):253-6
   PubMed Web of Science ®Google Scholar
• Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005;67(1):15-19
   PubMed Web of Science ®Google Scholar
• LoVerme J, Russo R, La Rana G, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 2006;319(3):1051-61
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152(7):1092-101
   PubMed Web of Science ®Google Scholar
• Loria F, Petrosino S, Mestre L, et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 2008;28(4):633-41
   PubMed Web of Science ®Google Scholar
• Redlich S, Ribes S, Schutze S, et al. Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 and Streptococcus pneumoniae R6 by microglial cells. J Neuroimmunol 2012;244(1-2):32-4
   PubMed Web of Science ®Google Scholar
• Redlich S, Ribes S, Schutze S, Nau R. Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections. J Neuroinflammation 2014;11:108
   PubMed Web of Science ®Google Scholar
• Kahlich R, Klima J, Cihla F, et al. Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J Hyg Epidemiol Microbiol Immunol 1979;23(1):11-24
   PubMedGoogle Scholar
• Keppel Hesslink MJ. New targets in pain, non-neuronal cells, and role of palmitoylethanolamide. Open Pain J 2012(5):12-23
   Google Scholar
• Nau R, Ribes S, Djukic M, Eiffert H. Strategies to increase the activity of microglia as efficient protectors of the brain against infections. Frontiers in Cellular Neuroscience 2014;8:138
   PubMed Web of Science ®Google Scholar
• Available from: www.dgn.org/images/stories/dgn/leitlinien/LL_2012/pdf/ll_34_ambulant_erworbene_bakterielle_eitrige_meningoenzephalitis.pdf
   Google Scholar